15.50MMarket Cap-1.79P/E (TTM)
2.281High2.160Low16.61KVolume2.280Open2.280Pre Close37.29KTurnover0.50%Turnover RatioLossP/E (Static)7.18MShares3.78052wk High-8.64P/B7.17MFloat Cap2.05052wk Low--Dividend TTM3.32MShs Float6.930Historical High--Div YieldTTM5.30%Amplitude1.800Historical Low2.245Avg Price1Lot Size
Neuraxis Stock Forum
UPDATE - NeurAxis Announces New Medical Policy Coverage with a Prominent Insurer for Over Five Million Lives Across Multiple States
Tuesday, 21st January at 1:45 pm
CARMEL, Ind., Jan. 21, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced medical policy coverage for Percutaneous Elec...
01/21/2025 - 06:00 AM
CARMEL, Ind., Jan. 21, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), with Molina Healthcare. Molina, with over 40 years in operation, has approximately 5.1 million...
Benzinga· 4 mins ago
NeurAxis Inc. Announces FDA 510(k) Clearance of RED for Testing and Evaluation of Patients with Chronic Constipation
Tuesday, 10th December at 9:00 am
RED has been designed to duplicate test performance of traditional balloon expulsion test (BET) and manual sensation testing devices without needing electronics or software.
NeurAxis Inc. will begin the process of commercially marketing RED and expects initial revenues in 1Q25 as there is a Category I CPT code assigned to t...
3 MINUTES AGO, 9:00 AM EST
VIA GLOBENEWSWIRE
📊⚡️📊
No comment yet